[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gerd-gastroesophageal-reflux-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gerd-gastroesophageal-reflux-disease":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,40,71,99,122,152,175,199,230,249,280,306,330,353],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100645230","an-observational-study-to-evaluate-the-efficacy-and-safety-of-k-cab-tabk-cab-odttegoprazan-in-gerd-patients-100645230",false,"NCT07678177","An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab.\u002FK-CAB ODT(Tegoprazan) in GERD Patients","A Multi-center, Prospective, Observational Study to Evaluate the Safety and Efficacy of K-CAB Tab.\u002FK-CAB ODT(Tegoprazan) in GERD Patients","Inclusion Criteria:\n\n1. Subjects over 19 years of age as of the date of consent\n2. Subjects with a total score of 8 or more in the Korean Gastroesophageal Reflux Disease Questionnaire (GerdQ) based on Visit 1\n3. Subjects who voluntarily decides to participate and agrees in writing to the consent form of the study\n\nExclusion Criteria:\n\n1. Subjects who have hypersensitivity reactions and a medical history of Benzimidazole or components of the investigational drug\n2. Subjects on Atazanavir, Nelfinavir, or Rilpivirine-containing medications\n3. Pregnant and lactating women","ALL","19 Years",{"count":19,"type":20},5384,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the status of AE and improvement effect of K-CAB Tab\u002FK-CAB ODT(Tegoprazan) 50mg in patients with GERD.",[24],"GERD (Gastroesophageal Reflux Disease)",[26],"IN_TPZ_N03","RECRUITING","2026-06-25",{"date":30,"type":31},"2026-07-01","ACTUAL",{"date":33,"type":31},"2023-03-07",{"date":35,"type":20},"2027-06-30",{"name":37,"class":38},"HK inno.N Corporation","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100563228","safety-and-effectiveness-of-egerd-device-to-reduce-gastroesophageal-reflux-disease-gerd-symptoms-100563228","NCT06613438","Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms","The Effect of Non-Invasive Electrical Stimulation Therapy on Gastroesophageal Reflux Disease (GERD)","Inclusion Criteria:\n\n1. Male or female, aged 22 - 75\n2. Has been typically suffering from at least three heartburn and\u002For regurgitation episodes per week during the past three months.\n3. Undergone a wireless (Bravo) pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2) in at least 2 monitoring days AND when averaged over all monitoring days of the test; or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD; or Undergone a catheter-based pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2); or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD.\n4. Able and willing to give informed consent for participation in the study and to comply with all study requirements, including operating the smartphone application.\n5. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.\n\nExclusion Criteria:\n\n1. Previously undergoing gastric or esophageal surgery\n2. Active peptic ulcer disease or symptomatic helicobacter\n3. Esophageal or gastric varices or esophageal peptic stricture\n4. Severe dysphagia\n5. History of suspected or confirmed esophageal or gastric cancer\n6. History of any other malignancy in the last 2 years\n7. Pregnant women or women intending to become pregnant during the trial period\n8. Uncontrolled diabetes mellitus, defined as HbA1c \\> 7.5%\n9. Severe cardiac conditions such as cardiac arrhythmia or ischemia or cardiac pacemaker \u002F defibrillator\n10. Having any implanted electrical device (e.g. sacral nerve stimulation, brain stimulator, others)\n11. Known allergy to the device's adhesives\u002Fpatches\n12. Severe pulmonary diseases\n13. History of significant multisystem diseases (e.g. kidney failure, liver failure)\n14. Known autoimmune or a connective tissue disorder (e.g. scleroderma, CREST-syndrome, Sjogren's Syndrome), requiring therapy in the preceding 2 years\n15. History of Barrett's esophagus\n16. Para-esophageal hiatal hernia\n17. Known history of sliding hiatal hernia ≥4 cm in the last 3 years\n18. Known history of erosive esophagitis Grade C or D (LA classification) in the past 5 years\n19. Obesity, defined as BMI\\>32\n20. History of gastroparesis\n21. History of fibromyalgia, epilepsy, endometriosis\n22. Umbilical hernia \\>3cm\n23. Past usage experience with the study device\n24. Those currently enrolled in any other interventional clinical study\n25. Inability to sign the informed consent\n26. Inability to understand and fill the reports and questionnaires included in the study\n27. Inability to follow the study requisites\n28. Other medical conditions\u002Fmedications that would interfere with subject safety or data collection in the opinion of the PI","22 Years","75 Years",{"count":50,"type":20},84,"INTERVENTIONAL",[53],"NA","The purpose of this research is to evaluate the safety and effectiveness of the eGERD device, which is a novel device for treating Gastroesophageal Reflux Disease (GERD).\n\nThe main questions this research aims to answer are:\n\n1. Does the eGERD device reduce acidity in the esophagus?\n2. Does the eGERD device reduce GERD symptoms such as heartburn and regurgitation?\n3. What medical problems do participants have when using the eGERD device?\n\nTo assess the acidity in the esophagus, a wireless standard-of-care capsule called Bravo will be placed in the participants esophagus (throat) for several days.\n\nTo assess GERD symptoms, participants will be requested to report symptoms they experience using a smartphone application.\n\nResearchers will compare a real version of the eGERD device to a sham version (a look-alike device that has no therapeutic effect) to see if the eGERD device is effective in treating GERD.",[24],[57,58,59,60],"Electrostimulation","Refulx","Regurgitation","eGERD","2026-06-22",{"date":63,"type":31},"2026-06-23",{"date":65,"type":31},"2024-09-15",{"date":67,"type":20},"2027-04",{"name":69,"class":38},"Gerd Care Medical Ltd",5,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":51,"phases":81,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":39},"100602592","evaluating-medication-adherence-of-patients-with-gastroesophageal-reflux-disease-with-support-of-the-smartphone-application-gerdcare-100602592","NCT07125521","Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of the Smartphone Application GERDCare","AppGERD","Inclusion Criteria:\n\n* ≥18 years old\n* Presents with typical GERD symptoms (regurgitation, heartburn)\n* Owns a smartphone and capable of using smartphone applications.\n\nExclusion Criteria:\n\n* Acute GI conditions (upper GI bleeding, acute peptic ulcer…)\n* GI malignancy (esophageal cancer, gastric cancer…)\n* Severe chronic comorbidities (heart failure, liver failure, chronic kidney disease…)\n* Pregnancy, alcohol abuse, mental health conditions impacting medication adherence or app usage","18 Years",{"count":80,"type":20},380,[53],"Adherence to GERD treatment, including medication, diet, and lifestyle, is essential for symptom control and complication prevention, yet adherence rates remain low due to various demographic and clinical factors. Digital therapeutics, particularly mobile health applications, have shown promising potential in supporting chronic disease management and improving patient outcomes.\n\nThe GERDCare mobile application was developed with direct input from gastrointestinal experts. It is designed to enhance treatment adherence and patient engagement by offering features such as educational resources, symptom tracking, medication reminders, and direct communication between patients and physicians.\n\nThe investigators are conducting a single-center, open-label, randomized controlled trial to evaluate the effectiveness of using GERDCare in improving patient adherence. Patients are followed up after four weeks of GERD treatment.",[24],[85,86,87,88],"GERD","mobile apps","mobile applications","medication adherence","2026-06-16",{"date":91,"type":31},"2026-06-17",{"date":93,"type":31},"2025-08-18",{"date":95,"type":20},"2026-08-31",{"name":97,"class":98},"Institute of Gastroenterology and Hepatology, Vietnam","OTHER",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":48,"enrollmentInfo":107,"targetDuration":4,"studyType":51,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100643555","endoscopic-injection-of-autologous-fat-derived-cells-svf-for-adults-with-refractory-gastroesophageal-reflux-disease-gerd-the-gerd-revive-pilot-study-100643555","NCT07638423","Endoscopic Injection of Autologous Fat-Derived Cells (SVF) for Adults With Refractory Gastroesophageal Reflux Disease (GERD). (The GERD-REVIVE Pilot Study)","Submucosal Injection of Autologous Stromal Vascular Fraction (SVF) at the Esophagogastric Junction for the Treatment of Gastroesophageal Reflux Disease (GERD): A Single-Arm Pilot Feasibility and Safety Study","GERD-REVIVE","Inclusion Criteria:\n\n* Adults 18-75 years; actionable GERD per Lyon 2.0 (e.g., AET \\>6% off therapy; or LA grade B-D, peptic stricture, Barrett's) and compatible symptoms. \\[2\\]\n* Refractory symptoms on optimized PPIs or PPI-dependent disease where intervention is contemplated. \\[2\\]\n* HRM excluding major motility disorders (per Chicago v4.0). \\[21\\]\n* Willing to undergo adipose harvest and autologous SVF therapy within a clinical trial framework.\n\nExclusion Criteria:\n\n* Hiatal hernia \\>3 cm or paraesophageal hernia; severe esophagitis with ulcers (grade B or more); Barrett's with dysplasia; strictures; achalasia\u002FEGJOO\u002Fspastic disorders. \\[2,21\\]\n* Coagulopathy, uncontrolled cardiopulmonary disease, pregnancy\u002Flactation.\n* Active infection\u002Fmalignancy significant for increased risk, at PI discretion.\n* Prior fundoplication or magnetic sphincter augmentation within 12 months.",{"count":108,"type":20},15,[53],"The purpose of this pilot clinical study is to evaluate the feasibility and safety of an innovative endoscopic treatment for adults with gastroesophageal reflux disease (GERD) that does not respond adequately to standard medications. The study focuses on the anti-reflux barrier between the esophagus and the stomach, which fails in patients with GERD. Instead of traditional surgery, this study explores a minimally invasive approach: injecting a specialized mixture of the patient's own fat-derived cells-known as the Stromal Vascular Fraction (SVF)-directly into the tissue at the esophagogastric junction during a standard endoscopy. The study is trying to answer two primary questions: Is it clinically feasible and safe to harvest, process, and endoscopically inject autologous SVF cells to support the anti-reflux barrier? Can this cell-based intervention help repair the tissue and improve the mechanical function of the barrier, allowing patients to reduce or completely stop their daily reliance on proton pump inhibitors (PPIs)? By answering these questions in a small group of 15 participants, this pilot trial aims to provide the foundational data necessary to design larger clinical studies in the future.",[24],"NOT_YET_RECRUITING","2026-06-05",{"date":115,"type":31},"2026-06-10",{"date":117,"type":20},"2026-07",{"date":119,"type":20},"2027-06",{"name":121,"class":98},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":51,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":148,"leadSponsor":150,"locationsCount":39},"100640288","new-topical-treatment-options-for-symptomatic-patients-with-nonerosive-gastroesophageal-reflux-disease-results-of-a-single-center-randomized-double-blind-placebo-controlled-crossover-trial-the-relief-trial-100640288","NCT07624383","New Topical tReatment Options for Symptomatic patiEnts With Nonerosive gastroesophageaL Reflux dIsease: rEsults oF a Single-center, Randomized, Double-blind, Placebo-controlled Crossover Trial. (The RELIEF Trial)","RELIEF","Inclusion Criteria:\n\n* Diagnosis of gastroesophageal reflux disease based on the presence of typical symptoms such as heartburn and or regurgitation for at least 6 months prior to the screening visit, confirmed by the investigator\n* Exclusion of erosive reflux disease, Barrett esophagus, and other esophageal abnormalities by upper gastrointestinal endoscopy within the last 6 months, confirmed by the investigator based on medical documentation\n* No use within 1 month prior to screening of proton pump inhibitors, H2 receptor antagonists, prokinetics such as itopride or prucalopride, GLP1 or GIP analogues, antibiotics, baclofen, tricyclic antidepressants, serotonin and or noradrenaline reuptake inhibitors, and no use within 1 week prior to screening of sucralfate, antacids, or esophageal mucosal protective agents\n* Presence of gastroesophageal reflux symptoms that negatively impact quality of life, as subjectively reported by the patient and confirmed by the investigator\n* Age 18 years or older at the time of screening\n* Women of childbearing potential must not be pregnant confirmed by a negative urine pregnancy test and must not be breastfeeding, or must be of non childbearing potential defined as surgically sterile, physiologically incapable of becoming pregnant, or at least 12 months post menopause\n* Women of childbearing potential with a male partner of reproductive potential must use a highly effective method of contraception from screening until 18 weeks after the last dose of the investigational medical device\n* Sexually active men with women of childbearing potential must agree to use barrier contraception such as condoms or abstain from sexual intercourse throughout the study period and for at least 7 days after the last dose of the investigational medical device\n* Ability to comply with all aspects of the clinical study\n* Male patients eligible for participation in the study.\n\nExclusion Criteria:\n\n* Women who are breastfeeding or have a positive urine pregnancy test at the baseline visit\n* Introduction of significant changes in diet or lifestyle during the study period\n* Presence of alarm symptoms at baseline including dysphagia or odynophagia, unintentional weight loss greater than 5 percent of baseline body weight, signs of gastrointestinal bleeding, anemia, palpable epigastric mass, or persistent vomiting lasting 7 to 10 days\n* Planned use during the study of antibiotics, probiotics, prebiotics, synbiotics, short chain fatty acids, proton pump inhibitors, H2 receptor antagonists, prokinetics such as itopride or prucalopride, GLP1 or GIP analogues, baclofen, tricyclic antidepressants, serotonin and or noradrenaline reuptake inhibitors, and use within 1 week prior to study start of sucralfate, antacids, or esophageal mucosal protective agents\n* Diagnosis of a severe disease such as malignancy\n* Planned hospitalization for any reason or presence of any severe comorbidity that in the opinion of the investigator constitutes a contraindication to study participation or may compromise patient safety\n* Current or recent history within 1 year prior to randomization of alcohol dependence or substance abuse\n* Active psychiatric disorders that in the opinion of the investigator may interfere with compliance with study procedures\n* Presence of unstable or uncontrolled cardiovascular disorders, moderate or severe heart failure classified as New York Heart Association class III or IV, or any clinically significant pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine or metabolic disorder, or any other medical condition that in the opinion of the investigator could affect study results or patient safety\n* Individuals who are employees of the study site, investigator, contract research organization, or sponsor\n* First degree relatives of employees of the study site, investigator, contract research organization, or sponsor\n* Individuals unable to attend all study visits or comply with study procedures.",{"count":130,"type":20},50,[53],"The goal of this randomized, double-blind, single-center clinical trial RELEIF is to learn if medical devices work to decrease symptoms of gastroesophageal reflux disease (GERD) in adults' patients. It will also teach us about the safety, tolerability and improvement of patient's quality of life during and after taking medical device. The main questions it aims to answer are:\n\n* Does medical device relieve reflux symptoms?\n* Does medical device improve the quality of life of patients with GERD symptoms? Researchers will compare medical device to a placebo (a look-alike substance that contains no drug) to see if medical device works in GERD gastroesophageal reflux disease .\n\nParticipants will:\n\n* Take medical device or a placebo every day (4 times a day) for 14 days\n* Stop taking medical device or placebo for 7 days (wash out period)\n* Switch the therapy for medical device or placebo for next 14 days\n* Visit the clinic 4 times during 35 days of this study for checkups and tests\n* Keep a diary of their symptoms and the number of times they use a medical device\n* Fill out the form to collect all necessary data.",[24,134],"NERD",[136,137,138,139,140,141,142,143],"gastroesophageal reflux disease","reflux","heartburn","medical device in reflux","regurgitation","quality of life in reflux disease","reflux symptoms","non erosive reflux disease","2026-05-28",{"date":146,"type":31},"2026-06-03",{"date":144,"type":20},{"date":149,"type":20},"2026-09-30",{"name":151,"class":38},"Cellmedis",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":51,"phases":162,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100595855","phase-3-a-study-comparing-the-effect-and-safety-of-linaprazan-glurate-to-lansoprazole-in-participants-with-erosive-esophagitis-ee-due-to-gastroesophageal-reflux-disease-gerd-100595855","NCT07037875","A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)","A Randomized, Phase 3, Double-blind, Double-dummy, Active Comparator-controlled Multicenter Study to Evaluate the Efficacy and Safety of 2 Doses of Linaprazan Glurate Compared to Lansoprazole in 4 or 8 Weeks Healing in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) of Los Angeles (LA) Grades A to D","Inclusion Criteria:\n\n1. The participant understands and voluntarily signs an Informed Consent Form (ICF) prior to initiation of any study-related assessments\u002Fprocedures.\n2. Male or female participants aged 18 to 80 years, inclusive, at the time of signing the ICF.\n3. The participant is willing and able to comply with all aspects of the protocol (including endoscopies, PK sampling, tablet and capsule swallowing, electronic device \\[e-device\\] completion, etc.).\n4. The participant has endoscopically confirmed EE due to GERD of LA grades A to D during the Screening Period as assessed in Central Review by an Independent Review Committee (IRC).\n\nExclusion Criteria:\n\n1. Ongoing infection with HP or diagnosis and treatment of HP infection within 6 weeks of randomization OR any treatment with antibiotics or bismuth containing drugs within 6 weeks of randomization.\n2. History or presence of any clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, neurological disease or disorder, or psychiatric diagnosis which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the study results or the participant's ability to participate in the study. The following examples are conditions that would exclude the patient from participating:\n\n   1. History of myocardial infarction\u002Facute coronary syndrome within 3 months prior to Screening.\n   2. History of ventricular arrhythmia or implanted cardioverter defibrillator.\n   3. Symptomatic congestive heart failure (New York Heart Association class 3-4).\n   4. Family history of\u002Fdiagnosis of hereditary arrhythmia syndrome.\n   5. History of adult asthma that required intensive treatment in an emergency room.\n3. History of malignancy of any organ system (other than completely treated localized basal cell carcinoma or non-metastatic squamous cell carcinoma of the skin or in situ cervical carcinoma), within the past 5 years.\n4. Solitary esophageal ulcer in the proximal two-thirds of the esophagus, untreated Barrett's esophagus or any other condition affecting the esophagus, including eosinophilic esophagitis; esophageal varices; viral or fungal infection; esophageal stricture\\*; a history of radiation therapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy to the esophagus; or any history of caustic or physiochemical trauma.\n\n   \\*Note: Patients with diagnosis of Schatzki's ring (mucosal tissue ring around lower esophageal sphincter) are eligible to participate, unless history of dilatation within 3 months of Screening.\n5. History of any surgical or medical condition which might significantly alter the GERD status or the absorption, distribution, metabolism, or excretion of drugs. The Investigator is to be guided by evidence of any of the following: history of major GI surgery such as gastrectomy, gastroenterostomy, any bariatric surgery, bowel resection, or transjugular intrahepatic portosystemic shunt. Nissen fundoplication is not exclusionary as long as the patient is eligible according to other criteria.\n6. Known severe atrophic gastritis as assessed from medical history or upper endoscopy during Screening.\n7. Zollinger-Ellison syndrome or other gastric acid hypersecretory conditions.\n8. History of treatment course with lansoprazole within 2 months prior to Screening.\n9. Current peptic ulcer.\n10. Body mass index (BMI) ≤ 18 and ≥ 40 kg\u002Fm² at Screening.","80 Years",{"count":161,"type":20},500,[163],"PHASE3","The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux disease (GERD), compared to lansoprazole, a commonly used medication. Researchers will also evaluate whether linaprazan glurate:\n\n* Reduces heartburn symptoms more effectively than lansoprazole\n* Is safe and well tolerated, based on physical exams, blood tests, and vital signs (heart rate, blood pressure, temperature, and breathing rate)\n* Causes any side effects during treatment\n* Has different effects depending on how much of the drug is in the blood\n* Works differently depending on participants' genes\n\nParticipants must be between 18 to 80 years old and have EE due to GERD confirmed by an endoscopy. Participants cannot join if they have an active Helicobacter pylori (HP) infection or were treated for HP in the past 6 weeks or have taken antibiotics or bismuth-containing drugs in the past 6 weeks.\n\nThe study is a randomized, double-blind, active comparator-controlled trial lasting up to 4 months. Randomized means that participants are assigned by chance (like flipping a coin) to one of the treatment groups and double-blind means neither the participants nor the study team will know which treatment is given. Participants will be placed into one of three groups (about 167 people in each group):\n\n* Linaprazan glurate 50 mg twice a day\n* Linaprazan glurate 50 mg once a day\n* Lansoprazole 30 mg once a day\n\nEveryone will take 2 tablets and 1 capsule by mouth daily for 8 weeks. Some tablets or capsules will be placebos (look like medicine but contain no active drug). Participants will:\n\n* Undergo an endoscopy in the beginning and after 4 weeks of treatment\n* If healing is not observed, another endoscopy may be done at 8 weeks\n* During the procedure, doctors will use a thin, flexible tube with a camera to look at the esophagus and take small tissue samples (biopsies)\n* Have blood and urine tests at clinic visits to check overall health\n* Receive electrocardiograms (ECGs) to monitor heart function\n* Complete daily questionnaires on an electronic device about symptoms and experiences",[24],{"date":167,"type":31},"2026-06-01",{"date":169,"type":31},"2025-09-11",{"date":171,"type":20},"2026-09",{"name":173,"class":38},"Cinclus Pharma Holding AB",75,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":51,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":198},"100612325","tlsa-versus-tbsa-surgical-approach-for-hiatal-hernia-with-gastroesophageal-reflux-disease-100612325","NCT07252115","TLSA Versus TBSA Surgical Approach for Hiatal Hernia With Gastroesophageal Reflux Disease","Multicenter Randomized Clinical Trial on the Efficacy and Safety of the Total Left-side Surgical Approach (TLSA) Versus the Traditional Bilateral Surgical Approach (TBSA) for Hiatal Hernia With Gastroesophageal Reflux Disease","Inclusion Criteria:\n\n* Patients aged 18 to 85 years.\n* Confirmed diagnosis of hiatal hernia (type I to IV).\n* Diagnosis of refractory GERD, defined as persistent symptoms despite receiving 40 mg daily omeprazole for 8-12 weeks.\n* GERD confirmed by either:\n* Increased esophageal acid exposure time (AET) on 24-hour pH monitoring, and\u002For\n* Endoscopic evidence of esophagitis.\n* Hiatal hernia diagnosis verified by both abdominal CT and gastroscopy.\n\nExclusion Criteria:\n\n* Presence of GERD without a hiatal hernia.\n* Esophageal motility disorder.\n* History of esophageal or other upper abdominal surgery.","85 Years",{"count":184,"type":20},143,[53],"Gastroesophageal reflux disease (GERD), characterized by pathological reflux of gastric contents, affects 10%-20% of the global population with Western predominance and escalating incidence over recent decades. Anatomical and functional abnormalities of the esophagogastric junction (EGJ) such as hiatal hernia (HH) is one of the major pathophysiological mechanisms. GERD elevates risks for Barrett esophagus, esophageal adenocarcinoma and interstitial pulmonary fibrosis, while characteristic symptoms including reflux and heartburn substantially impair quality of life (QoL). Proton pump inhibitors (PPIs) are used to alleviate symptoms and prevent reflux-related esophageal mucosal damage, but may cause long-term adverse effects.\n\nAnti-reflux surgery (ARS) is a well-established therapeutic option for patients with anatomical abnormalities, chronic PPI-refractory symptoms or unwilling to take lifelong PPIs. It provides comparable or potentially superior efficacy to PPIs, especially in reconstructing anatomical structures and addressing EGJ functional deficiencies. Maximize patients' QoL while minimizing side effects is priority for ARS. Despite advancements in surgical techniques, ARS remains invasive and is associated with inherent mechanical complications, including dysphagia and potential vagus nerve injury. A growing consensus recognizes that hepatic vagus nerve injury, occurring in a significant proportion of patients following ARS, potentially contributes to postoperative dysfunctions such as delayed gastric emptying, impaired reflux control, dyspeptic symptoms, cholelithiasis, ultimately diminishing QoL.\n\nAlthough the traditional bilateral surgical approach (TBSA) is widely used, its requisite dissection of the lesser omentum invariably injures or severs the hepatic branch of the vagus nerve. The hepatic branch of the vagus arises from the anterior trunk and predominantly innervates the gastric antrum, pylorus, proximal duodenum and biliary tract. Functionally, it mediates a spectrum of vital physiological process including hepato-gastric reflexes that facilitate gastric motility via osmotic sensing, as well as glucose-sensitive reflexes that inhibit gastric motility and delay gastric emptying. Furthermore, hepatic branch is involved in food intake and metabolic homeostasis, and it exerts parasympathetic control over the coordinated contraction of the gallbladder and sphincter of Oddi. However, the functional preservation of the hepatic branch of the vagus nerve during ARS remains poorly understood, with limited clinical evidence and absent robust guidelines.\n\nBased on our preliminary findings, we initiated a long-term evaluation of the total left-side approach (TLSA), a nerve-sparing strategy that preserves the lesser omentum and hepatogastric ligament to safeguard the hepatic branch of the vagus nerve, with the aim of enhancing postoperative QoL.",[188,24],"Hernia, Hiatal","2025-11-25",{"date":191,"type":31},"2025-11-26",{"date":193,"type":31},"2024-04-04",{"date":195,"type":20},"2026-12-31",{"name":197,"class":98},"Beijing Friendship Hospital",2,{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":51,"phases":209,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":39},"100606689","sling-fiber-preservation-poem-vs-conventional-poem-for-reducing-post-poem-gerd-100606689","NCT07178821","Sling-Fiber Preservation POEM vs. Conventional POEM for Reducing Post-POEM GERD","Sling-Fiber Preservation POEM vs. Conventional POEM for Reducing Post-POEM GERD: A Randomized Control Trial","SFP-POEM","Inclusion Criteria (Participants must meet all of the following):\n\n* Age ≥ 18 years\n* Diagnosis of achalasia (Type I-III) per Chicago Classification v3.0\n* Deemed appropriate candidates for POEM\n* Ability to provide informed consent\n\nExclusion Criteria (Participants will be excluded if any of the following apply):\n\n* Spastic motility disorders other than achalasia type I-III (e.g. diffuse esophageal spasm, jackhammer esophagus, EGJ outflow obstruction)\n* Sigmoid esophagus\n* Prior surgical myotomy (e.g., Heller myotomy)\n* Contraindications to endoscopy or general anesthesia\n* Pregnancy or actively breastfeeding\n* Significant cardiopulmonary comorbidities that preclude safe endoscopic intervention\n* Coagulopathy or portal hypertension\n* Unwillingness or inability to complete follow-up assessments",{"count":208,"type":20},120,[53],"Peroral endoscopic myotomy (POEM) is an effective, minimally invasive treatment for achalasia, offering excellent rates of symptom relief. However, a significant drawback is the high incidence of gastroesophageal reflux disease (GERD) following the procedure. One proposed technical modification, the selective preservation of the sling fibers during gastric myotomy (SFP-POEM), may reduce this risk without compromising efficacy as compared to a conventional POEM procedure, which includes myotomy of the sling fibers. In this study, adults with achalasia will be randomly assigned to receive one of the two POEM technical approaches. Researchers will monitor whether preserving sling fibers reduces the rates of reflux esophagitis (classified as Los Angeles Grade B or higher) on follow-up endoscopy. Participants will be followed for up to 1 year after the procedure.",[212,24],"Achalasia, Esophageal",[214,215,216,217,205,218,85,219,220],"Achalasia","POEM","Peroral Endoscopic Myotomy","Sling Fiber Preservation","Gastroesophageal Reflux","Reflux Esophagitis","Randomized Controlled Trial","2025-10-20",{"date":223,"type":31},"2025-10-22",{"date":225,"type":20},"2025-12-01",{"date":227,"type":20},"2028-01-01",{"name":229,"class":98},"University of California, Irvine",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":51,"phases":236,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":39},"100602727","evaluating-medication-adherence-of-patients-with-gastroesophageal-reflux-disease-with-support-of-smartphone-application-gerdcare-100602727","NCT07127276","Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of Smartphone Application GERDCare",{"count":80,"type":20},[53],"Adherence to GERD treatment, including medication, diet, and lifestyle, is essential for symptom control and complication prevention, yet adherence rates remain low due to various demographic and clinical factors. Digital therapeutics, particularly mobile health applications, have shown promising potential in supporting chronic disease management and improving patient outcomes.\n\nThe GERDCare mobile application was developed with direct input from gastrointestinal experts. It is designed to enhance treatment adherence and patient engagement by offering features such as educational resources, symptom tracking, medication reminders, and direct communication between patients and physicians.\n\nWe are conducting a single-center, open-label, randomized controlled trial to evaluate the effectiveness of using GERDCare in improving patient adherence. Patients are followed up after four weeks of GERD treatment.",[24],[85,240,86,87,88],"Gastroesophageal reflux disease","2025-08-10",{"date":243,"type":31},"2025-08-17",{"date":245,"type":20},"2025-08-15",{"date":247,"type":20},"2025-10-31",{"name":97,"class":98},{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":257,"sex":16,"minAge":78,"maxAge":159,"enrollmentInfo":258,"targetDuration":4,"studyType":51,"phases":260,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":39},"100602307","the-influence-of-specialized-food-products-based-on-ice-cream-on-esophageal-motility-100602307","NCT07121803","The Influence of Specialized Food Products Based on Ice-Cream on Esophageal Motility","Analysis of Effects of Specialized Food Products Based on Ice-Cream on Esophageal Motility","MICE","Inclusion Criteria:\n\n* willingness to participate based on signed written informed consent;\n* controlled glycemia. If stable glycemia is achieved on treatment, the following requirements should be met:\n* no qualitative changes in treatment within 6 months before enrollment (i.e., the introduction of a new antidiabetic therapy);\n* doses of anti-diabetic medications should be stable for 6 month in patients who receive metformin, gliptins, sulfonylureas, sodium\u002Fglucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 agonists (GLP-1) or insulin.\n* no new medications during participation in the study\n\nExclusion Criteria:\n\n* Pregnancy and breastfeeding;\n* Liver cirrhosis based on liver histology, or liver stiffness measurement (LSM \\> or = 14 kPa by Fibroscan), or APRI \\> or= 1; or BARD score \\> or = 2.\n* Diarrhea of any type (watery stool more than 3 times a day).\n* Chronic heart failure (I-IV class by NYHA).\n* Past major abdominal or chest surgery, including bariatric procedures and fundoplication (except appendectomy or cholecystectomy performed more than a year before enrollment).\n* Achalasia and esophago-gastric junction outflow obstruction\n* Major esophageal motility disorders according to Chicago IV classification.\n* Clinically relevant acute cardiovascular event within 6 months prior to screening.\n* Uncontrolled arterial hypertension despite optimal anti-hypertensive therapy.\n* Diabetes mellitus type 1.\n* The level of glycated hemoglobin \\[HbA1c\\] \\>9.0%.\n* Hypersensitivity to the studied product or any of its components, including lactose intolerance.\n* The intake of any pharmaceutical agents with known influence on esophageal motility (including, but not limited to: beta-blockers, calcium channel blockers, m-cholinoblockers, myorelaxants, antidepressants, tranquilizers, prokinetic agents)\n* Any medical conditions that may significantly affect life expectancy, including known cancers;\n* Any clinically significant immunological, endocrine, hematological, gastrointestinal, neurological, tumor or psychiatric diseases;\n* Mental instability or incapacity, which may impact the ability to give informed consent, take part in the study, or affect the ability to comply with the requirements of the study protocol;\n* Inability to tolerate high-resolution esophageal manometry without sedation, at least in part.",true,{"count":259,"type":20},30,[53],"This study aims to assess the influence of specialized products based on ice cream on esophageal motility",[263,24],"Ineffective Esophageal Motility",[265,266,267,268,269,270],"Esophageal motility","Specialized foods","icecream","esophagus","motility","high-resolution esophageal manometry","2025-08-07",{"date":273,"type":31},"2025-08-14",{"date":275,"type":31},"2025-07-01",{"date":277,"type":20},"2025-12-31",{"name":279,"class":98},"Federal State Budgetary Scientific Institution \"Federal Research Centre of Nutrition, Biotechnology",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":287,"maxAge":4,"enrollmentInfo":288,"targetDuration":290,"studyType":21,"phases":4,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":302,"leadSponsor":304,"locationsCount":4},"100594704","ppi-refractory---gerd-mechanisms-in-systemic-sclerosis-100594704","NCT07022912","PPI Refractory - GERD Mechanisms in Systemic Sclerosis","Objective Assessment of Gastrointestinal Involvement in Patients With Systemic Sclerosis and Gastroesophageal Reflux Symptoms Refractory to Proton Pump Inhibitors.","Inclusion Criteria:\n\n* Systemic sclerosis by ACR\u002FEULAR 2023 criteria AND\u002FOR Leroy Medsger classification criteria\n* Reflux symptoms (Heartburn AND\u002FOR Regurgitation), at least 3 times a week over the last 3 months despite PPI therapy\n\nExclusion Criteria:\n\n* Previous surgery altering the anatomy or motility of the upper digestive tract, including fundoplication, esophageal myotomy, gastrectomy, or bariatric surgery.\n\nSevere pulmonary or cardiac disease requiring intravenous vasodilators, continuous oxygen therapy, or ventricular assist devices, preventing the performance of gastrointestinal motility tests.\n\nPregnancy at the time of evaluation or planned pregnancy during the duration of the study.\n\nNeuromuscular disorders other than systemic sclerosis that may affect gastrointestinal motility.\n\nPrior diagnosis of functional gastrointestinal disorders, such as irritable bowel syndrome or functional dyspepsia, that may interfere with the interpretation of results.","16 Years",{"count":289,"type":20},147,"5 Months","The goal of this observational study is to learn about the mechanisms of gastroesophageal reflux disease (GERD) in patients with systemic sclerosis (SSc) who continue to experience reflux symptoms despite treatment with proton pump inhibitors (PPIs). The main question it aims to answer is:\n\nWhat are the underlying gastrointestinal mechanisms contributing to PPI-refractory reflux symptoms in patients with SSc?\n\nParticipants with a confirmed diagnosis of SSc and persistent reflux symptoms despite PPI therapy will undergo standard-of-care diagnostic tests, including high-resolution esophageal manometry and pH-impedance monitoring. Clinical data and test results will be collected and analyzed to identify patterns of motility dysfunction and reflux characteristics associated with refractory symptoms.",[293,24],"Systemic Sclerosis (SSc)",[295,296,297],"GERD mechanisms","gastrointestinal involvement","systemic sclerosis","2025-06-06",{"date":300,"type":31},"2025-06-15",{"date":275,"type":20},{"date":303,"type":20},"2027-07-01",{"name":305,"class":98},"Hospital Universitari Vall d'Hebron Research Institute",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":257,"sex":16,"minAge":78,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":39},"100587435","normal-values-of-ambulatory-24-hour-oesophageal-ph-impedance-monitoring-in-an-indian-cohort-of-participants-100587435","NCT06928350","Normal Values of Ambulatory 24-hour Oesophageal pH-impedance Monitoring in an Indian Cohort of Participants","Inclusion Criteria:\n\n* Adult 18-50 years of age\n* No gastro-intestinal symptoms\n* No past GI or thoracic or spine surgery\n* Not on any medications\n* No history of recent alcohol intake (0 drinks in the past 1 month)\n* Non smoker\n* Normal BMI (18.5-22.9)\n\nExclusion Criteria:\n\n* Any diagnosed systemic or organ specific disease (liver\u002Fkidney\u002Fheart\u002Fneurological disease, DM\u002FHTN\u002FThyroid disease\u002F connective tissue disorder\u002Finflammatory bowel disease\u002F irritable bowel syndrome)\n* GERD symptoms\u002F functional dyspepsia\n* Pregnant women or breast-feeding women\n* Helicobacter pylori infection","50 Years",{"count":130,"type":20},"This study aims to determine normal 24-hour pH-impedance monitoring values, including acid exposure time (AET), in healthy Indian adults. It will help improve GERD diagnosis in India by providing population-specific data. The study will also explore how diet, body position, and nighttime reflux affect acid exposure. Healthy volunteers aged 18 and above will be monitored for 24 hours.",[24],[317,85,318,319,320,321],"24- hour pH impedance monitoring","Acid exposure","Healthy volunteers","Indian cohort","reflux episodes",{"date":323,"type":31},"2025-06-11",{"date":325,"type":31},"2025-04-01",{"date":327,"type":20},"2026-05-01",{"name":329,"class":98},"Asian Institute of Gastroenterology, India",{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":51,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":352},"100593281","a-blinded-randomized-clinical-study-of-refluxstop-compared-with-nissen-fundoplication-in-the-treatment-of-gerd-100593281","NCT07004400","A Blinded Randomized Clinical Study of RefluxStop™ Compared With Nissen Fundoplication in the Treatment of GERD","A Blinded Randomized Clinical Investigation of RefluxStop™ Compared With Nissen Fundoplication in the Treatment of Gastroesophageal Reflux Disease (GERD).","RENEW RCT","Inclusion Criteria:\n\n1. Willing and able to provide informed consent and to participate in the clinical investigation;\n2. Age ≥ 18 years or according to local legal age of adulthood at the location of the test site if older;\n3. Documented GERD present for ≥ 12 months. Typical symptoms are defined as heartburn, which is a burning sensation often presented as a substernal pain;\n4. 24-hour pH monitoring proven GERD with pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be \\\u003C 4 for ≥ 4.5% of time during a 24-hour monitoring);\n5. Suitable to undergo general anesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator\n\nExclusion Criteria:\n\n1. \\> 8 cm sliding hernia and paraesophageal hernia; no mesh is allowed;\n2. Manometry verified lack of or moderate or severe weak peristalsis in esophagus with DCI \\\u003C300 or pathologic LOS function including hypercontractability, spasm or pathologic nonrelaxing functionality (the latter defined as coordinated swallows in less than 70% of wet swallows or median IRP\\>15mmHg). Hypercontractability defined as DCI \\>8'000 or pressure \\>45 mmHg. Thus, excluding from the study the rare diseases achalasia, scleroderma, and nutcracker esophagus, however, including mild esophageal motility disorder patients with mildly weak peristalsis;\n3. History of bariatric or anti-reflux surgery;\n4. Female subjects who are pregnant or nursing;\n5. Known sensitivity or allergies to silicone materials;\n6. Intraoperative findings determined by the investigator that may result in unfavorable conduct of the clinical investigation procedure (as outlined in the IFU);\n7. Subjects that are unable to comply with the clinical investigation requirements (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the clinical investigation according to the investigator's judgement);",{"count":339,"type":20},200,[53],"This study will evaluate if the RefluxStop™ device will treat your acid reflux and improve your symptoms and how it compares to the standard surgical treatment for GERD, the Nissen fundoplication.",[24],"2025-05-27",{"date":345,"type":31},"2025-06-04",{"date":347,"type":20},"2025-08-01",{"date":349,"type":20},"2026-12-01",{"name":351,"class":38},"Implantica CE Reflux Ltd.",4,{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":362,"conditions":363,"keywords":366,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":39},"100554170","the-voice-of-reflux---backflow-of-gastric-juice-leads-to-irritation-of-the-vocal-folds-are-there-typical-differences-in-the-voice-100554170","NCT06495606","\"The Voice of Reflux\" - Backflow of Gastric Juice Leads to Irritation of the Vocal Folds: Are There Typical Differences in the Voice?","The Voice of Reflux: Typical Vocal Biomarkers in Patients With Gastroesophageal Reflux Disease","Inclusion Criteria:\n\n* Age above 18\n* Informed consent\n* Undergoing gastroesophageal reflux diagnostic according to the current standard\n* Basic reading skills in German or English\n\nExclusion Criteria:\n\n* Age below 18\n* No basic reading skills in German or English\n* Diseases with altered voice\n* Laryngopharyngeal surgery or interventions in the past",{"count":361,"type":20},94,"If gastric juice refluxes back into the oesophagus and up into the throat\u002Fpharynx\u002Fmouth area, causing discomfort or injury, this is known as reflux disease (reflux). Classic symptoms include a burning pain in the middle of the upper abdomen, chest or throat (so-called heartburn), regurgitation of food (acid regurgitation), foreign body sensation in the throat area. There are also changes in the voice, hoarseness, difficulty clearing the throat, difficulty swallowing or a dry, irritating cough due to the chemical irritation of the vocal folds by the gastric juice. There are various causes of reflux. Often there is a weakness of the lower oesophageal sphincter or a hiatal hernia, which favours the reflux of gastric juice. Sometimes there are also movement disorders in the oesophagus or stomach with insufficiently efficient transport of food and liquids.\n\nAfter a consultation with a specialist, three further standard examinations are ordered as a matter of priority for a proper reflux diagnosis:\n\n* Gastroscopy: a tube-shaped camera can be used to view the mouth, pharynx, throat, oesophagus, stomach and the beginning of the duodenum and, if necessary, small tissue samples can be taken.\n* Oesophageal manometry: A pressure measurement of the oesophagus can detect movement disorders or a malfunction of the oesophagus and sphincter.\n* 24-hour impedance pH measurement: A small tube is placed in the oesophagus through the nose and left there for 24 hours. The probe measures how often gastric juice flows back to a certain level and how acidic this juice is.\n\nThese examinations allow reflux to be definitively diagnosed, possible causes to be identified, any further investigations to be considered and the best possible treatment to be suggested.\n\nIn these times of rapidly advancing digitalisation and increasing technical possibilities, we ask ourselves the following: If reflux changes the voice - would it be possible to detect reflux disease with voice samples the other way round? Studies are already underway in several other medical fields that are successfully analysing voice and speech samples and looking for typical changes in the voice pattern for diseases.\n\nOur theory: Alterations typical for reflux can be found in voice samples. In future, voice samples can be used as a harmless, simple and inexpensive initial assessment for reflux.\n\nThe questions of our research project are therefore:\n\n1. Do patients with confirmed reflux have a typical pattern of changes in their voice?\n2. Can these changes be reliably determined via voice analyses?\n3. Could a simple voice sample become the first basic examination for reflux patients in the future?\n\nProcedure and duration of the study:\n\nThis project will be conducted exclusively at the Inselspital Bern (monocentric = 1 hospital, national = 1 country). All persons who receive the above-mentioned standard examination for a reflux clarification are eligible for participation. The standard examination will either confirm or rule out reflux. For our research project, we want to investigate two situations:\n\n1. firstly, as a baseline, we would like to examine the voices of 47 participants with confirmed reflux and compare them with the voices of 47 participants with confirmed absence of reflux disease.\n2. secondly, we would like to check the voices of participants with confirmed reflux again 5 months after the start of treatment and compare them with their initial situation.\n\nParticipants will complete a questionnaire and provide a voice sample (short simple recording into a microphone). Participation in the research project does not require any additional hospital visits or consultation appointments and lasts a maximum of 5 months.\n\nThe voice samples are then digitised, analysed, evaluated and searched for typical patterns of change by us in collaboration with the CSEM Neuchâtel (Centre Suisse Électronique et de Microtechnique). CSEM is an internationally recognised Swiss technology innovation centre that will help us with the sophisticated evaluation of the voice analyses. As these are simple voice recordings into a microphone, there are no additional clarifications, interventions or risks involved in participating. Data will be stored in encrypted form in a SharePoint database in strict compliance with all data protection regulations and will only be used for the agreed research project. Results are expected in 2025.",[364,365],"GERD Gastroesophageal Reflux Disease","Laryngopharyngeal Reflux Disease",[85,367,368,369,370],"LPRD","Reflux","Voice","Vocal Biomarker","2024-07-03",{"date":373,"type":31},"2024-07-11",{"date":375,"type":31},"2024-04-10",{"date":377,"type":20},"2025-08",{"name":379,"class":98},"Insel Gruppe AG, University Hospital Bern"]